Literature DB >> 28237764

Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.

Saikat Banerjee1, Heliang Shi1, Marisa Banasik1, Hojin Moon1, William Lees2, Yali Qin1, Andrew Harley1, Adrian Shepherd2, Michael W Cho3.   

Abstract

The membrane proximal external region (MPER) of HIV-1 gp41 is targeted by broadly neutralizing antibodies (bnAbs) 4E10 and 10E8. In this proof-of-concept study, we evaluated a novel multi-immunogen vaccine strategy referred to as Incremental, Phased Antigenic Stimulation for Rapid Antibody Maturation (IPAS-RAM) to induce 4E10/10E8-like bnAbs. Rabbits were immunized sequentially, but in a phased manner, with three immunogens that are progressively more native (gp41-28×3, gp41-54CT, and rVV-gp160DH12). Although nAbs were not induced, epitope-mapping analyses indicated that IPAS-RAM vaccination was better able to target antibodies towards the 4E10/10E8 epitopes than homologous prime-boost immunization using gp41-28×3 alone. MPER-specific rabbit monoclonal antibodies were generated, including 9F6. Although it lacked neutralizing activity, the target epitope profile of 9F6 closely resembled those of 4E10 and 10E8 (671NWFDITNWLWYIK683). B-cell repertoire analyses suggested the importance of co-immunizations for maturation of 9F6, which warrants further evaluation of our IPAS-RAM vaccine strategy using an improved priming immunogen.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibody maturation; HIV-1; MPER; NGS; Neutralizing antibody; Next-generation sequencing; Rabbit; Vaccine; gp41

Mesh:

Substances:

Year:  2017        PMID: 28237764      PMCID: PMC5385849          DOI: 10.1016/j.virol.2017.02.015

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  67 in total

1.  Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion.

Authors:  I Muñoz-Barroso; K Salzwedel; E Hunter; R Blumenthal
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 2.  The role of antibodies in HIV vaccines.

Authors:  John R Mascola; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

3.  High-resolution antibody dynamics of vaccine-induced immune responses.

Authors:  Uri Laserson; Francois Vigneault; Daniel Gadala-Maria; Gur Yaari; Mohamed Uduman; Jason A Vander Heiden; William Kelton; Sang Taek Jung; Yi Liu; Jonathan Laserson; Raj Chari; Je-Hyuk Lee; Ido Bachelet; Brendan Hickey; Erez Lieberman-Aiden; Bozena Hanczaruk; Birgitte B Simen; Michael Egholm; Daphne Koller; George Georgiou; Steven H Kleinstein; George M Church
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-17       Impact factor: 11.205

4.  Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.

Authors:  M W Cho; Y B Kim; M K Lee; K C Gupta; W Ross; R Plishka; A Buckler-White; T Igarashi; T Theodore; R Byrum; C Kemp; D C Montefiori; M A Martin
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  A Hidden Markov Model approach to variation among sites in rate of evolution.

Authors:  J Felsenstein; G A Churchill
Journal:  Mol Biol Evol       Date:  1996-01       Impact factor: 16.240

6.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

7.  Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope.

Authors:  Bruno E Correia; Yih-En Andrew Ban; Margaret A Holmes; Hengyu Xu; Katharine Ellingson; Zane Kraft; Chris Carrico; Erica Boni; D Noah Sather; Camille Zenobia; Katherine Y Burke; Tyler Bradley-Hewitt; Jessica F Bruhn-Johannsen; Oleksandr Kalyuzhniy; David Baker; Roland K Strong; Leonidas Stamatatos; William R Schief
Journal:  Structure       Date:  2010-09-08       Impact factor: 5.006

8.  Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure.

Authors:  Saikat Banerjee; Heliang Shi; Habtom H Habte; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2016-01-21       Impact factor: 3.616

9.  Broad neutralization coverage of HIV by multiple highly potent antibodies.

Authors:  Laura M Walker; Michael Huber; Katie J Doores; Emilia Falkowska; Robert Pejchal; Jean-Philippe Julien; Sheng-Kai Wang; Alejandra Ramos; Po-Ying Chan-Hui; Matthew Moyle; Jennifer L Mitcham; Phillip W Hammond; Ole A Olsen; Pham Phung; Steven Fling; Chi-Huey Wong; Sanjay Phogat; Terri Wrin; Melissa D Simek; Wayne C Koff; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Nature       Date:  2011-09-22       Impact factor: 49.962

10.  Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies.

Authors:  Bryan Briney; Devin Sok; Joseph G Jardine; Daniel W Kulp; Patrick Skog; Sergey Menis; Ronald Jacak; Oleksandr Kalyuzhniy; Natalia de Val; Fabian Sesterhenn; Khoa M Le; Alejandra Ramos; Meaghan Jones; Karen L Saye-Francisco; Tanya R Blane; Skye Spencer; Erik Georgeson; Xiaozhen Hu; Gabriel Ozorowski; Yumiko Adachi; Michael Kubitz; Anita Sarkar; Ian A Wilson; Andrew B Ward; David Nemazee; Dennis R Burton; William R Schief
Journal:  Cell       Date:  2016-09-08       Impact factor: 41.582

View more
  7 in total

1.  An Engineered Biomimetic MPER Peptide Vaccine Induces Weakly HIV Neutralizing Antibodies in Mice.

Authors:  Shuai Shao; Wei-Chiao Huang; Cuiyan Lin; Mark D Hicar; Celia C LaBranche; David C Montefiori; Jonathan F Lovell
Journal:  Ann Biomed Eng       Date:  2019-12-12       Impact factor: 3.934

2.  Myomedin scaffold variants targeted to 10E8 HIV-1 broadly neutralizing antibody mimic gp41 epitope and elicit HIV-1 virus-neutralizing sera in mice.

Authors:  Milan Kuchař; Petr Kosztyu; Veronika Daniel Lišková; Jiří Černý; Hana Petroková; Eliška Vróblová; Michal Malý; Lucie Vaňková; Michal Křupka; Leona Rašková Kafková; Pavlína Turánek Knotigová; Jarmila Dušková; Jan Dohnálek; Josef Mašek; Jaroslav Turánek; Milan Raška; Petr Malý
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

3.  Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.

Authors:  Vikram Srivastava; Ling Niu; Kruttika S Phadke; Bryan H Bellaire; Michael W Cho
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

Review 4.  Tracing Antibody Repertoire Evolution by Systems Phylogeny.

Authors:  Alexander Dimitri Yermanos; Andreas Kevin Dounas; Tanja Stadler; Annette Oxenius; Sai T Reddy
Journal:  Front Immunol       Date:  2018-10-02       Impact factor: 7.561

5.  Identification of variant HIV envelope proteins with enhanced affinities for precursors to anti-gp41 broadly neutralizing antibodies.

Authors:  Hong Zhu; Elizabeth Mathew; Sara M Connelly; Jeffrey Zuber; Mark Sullivan; Michael S Piepenbrink; James J Kobie; Mark E Dumont
Journal:  PLoS One       Date:  2019-09-10       Impact factor: 3.240

Review 6.  Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies.

Authors:  Zehua Sun; Lixin Yan; Jiansong Tang; Qian Qian; Jerica Lenberg; Dandan Zhu; Wan Liu; Kao Wu; Yilin Wang; Shiqiang Lu
Journal:  Virus Res       Date:  2017-10-16       Impact factor: 3.303

7.  Automated analysis of immunosequencing datasets reveals novel immunoglobulin D genes across diverse species.

Authors:  Vinnu Bhardwaj; Massimo Franceschetti; Ramesh Rao; Pavel A Pevzner; Yana Safonova
Journal:  PLoS Comput Biol       Date:  2020-04-27       Impact factor: 4.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.